Alpine Global Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alpine Global Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,119	Closed	-$234K	–	345
2020 Q2	$234K	Buy	+2,119	New	+$234K	0.04%	253
2016 Q3	–	Sell	-7,407	Closed	-$1.05M	–	134
2016 Q2	$1.05M	Buy	+7,407	New	+$1.09M	0.48%	40

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Alpine Global Management's JAZZ Position: Q3 2020 in Review

Alpine Global Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 2,119 shares — an estimated $234K sold.

Alpine Global Management first reported a position in JAZZ in Q2 2016 and held it in 2 quarters. The position peaked at $1.05M in Q2 2016. 389 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

Alpine Global Management reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Alpine Global Management sold 2,119 Jazz Pharmaceuticals shares in Q3 2020, an estimated $234K.
Alpine Global Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 2 quarters.
Alpine Global Management's Jazz Pharmaceuticals position peaked at $1.05M in Q2 2016.
389 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Alpine Global Management's 13F filing for Q3 2020, filed 12 Nov 2020.